Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection; Discovery of Pibrentasvir, a pan-genotype HCV NS5A inhibitor with a high barrier to viral resistance
Dr. John Randolph, Sr. Principal Research Scientist, CMeC, Abbvie, Inc.
Date / Time:
Thursday, September 26, 2019 - 4:00pm
Dr. Jo. V. Davisson